Blood Virus Testing Market

The exact queued 24LifeSciences page for the Blood Virus Testing Market was not retrievable during this research pass, and the matching publicly indexed report extract leaves its 2024 market size, 2031 forecast and CAGR fields blank. Accordingly, this overview preserves the report topic and available scope but does not fabricate market-size, CAGR or regional-share values. Quantitative analysis below is limited to figures supported by WHO, FDA and other authoritative sources.

Blood virus testing encompasses serologic, antigen and nucleic-acid methods used to identify viral infections in blood for clinical diagnosis, donor screening and disease monitoring. The commercial landscape includes laboratory immunoassays, molecular PCR/NAT systems, rapid or point-of-care tests, controls and associated reagents. Blood-bank demand is especially stringent because a false-negative donor result can transmit infection to recipients, while clinical testing spans diagnosis, confirmation, viral-load monitoring and treatment pathways.

WHO recommends that all donated blood be screened for HIV, hepatitis B, hepatitis C and syphilis before use. Its June 2026 blood-safety update reports 120.4 million blood donations globally and notes that some countries still cannot screen every donation for one or more required infections. This makes blood safety a recurring reagent-and-platform market tied to every donation rather than an optional diagnostic program.

Disease burden also sustains clinical demand. WHO's July 2026 hepatitis B update estimates 240 million people living with chronic HBV infection and 0.9 million new infections annually, while hepatitis C affects an estimated 47 million people with roughly 0.9 million new infections per year. Testing is essential because viral hepatitis cannot be differentiated reliably on symptoms alone and because linkage to treatment depends on laboratory confirmation and, in many settings, molecular quantification.

Technology competition centers on reducing the diagnostic window, combining targets and improving laboratory throughput. FDA's donor-screening list includes serologic assays for HIV, HBV, HCV and HTLV alongside multiplex NAT systems. Roche's cobas MPX directly detects HIV-1, HIV-2, HCV and HBV nucleic acids on high-throughput cobas 6800/8800 systems, while Abbott's Alinity s platform supports CMIA-based HIV Ag/Ab, HBsAg, anti-HBc and anti-HCV donor screening.

The exact queued page is unavailable, but matching public report architecture for this topic consistently lists the following legacy type and application scope. Because these labels are unusually broad for virus-specific testing, the analytical sections below preserve them while clearly relating each category to clinically relevant viral-testing use.

Mandatory blood-donor screening creates recurring test demand

WHO states that all donated blood should be screened for HIV, hepatitis B, hepatitis C and syphilis before release. Because screening is linked to each donation, blood-bank demand is driven by donation volume, test algorithms and quality requirements rather than symptomatic patient presentation.

Large chronic viral populations sustain diagnostic and monitoring demand

WHO estimates 240 million people living with chronic hepatitis B and 47 million with chronic hepatitis C. Diagnosis, linkage to care and treatment monitoring require laboratory testing, creating recurring demand beyond the transfusion-safety segment.

NAT reduces the window period and supports multiplex efficiency

Nucleic-acid testing detects viral RNA or DNA directly, shortening the interval between infection and detectable serologic response. Multiplex systems such as cobas MPX combine HIV-1/2, HCV and HBV targets, improving high-volume blood-screening efficiency at the cost of higher equipment and validation requirements.

Quality gaps remain significant across lower-income settings

WHO reports that only 63% of blood-screening laboratories globally participated in external quality-assessment schemes, with participation much lower in low-income countries. This creates a market-development need for controls, training, standardized assays and simpler quality-management workflows.

Regulatory approval is a material barrier to market entry

Donor-screening assays operate under stringent biologics and IVD regulation because errors can affect transfusion safety. FDA maintains dedicated lists of licensed donor-screening assays by infectious agent. The regulatory burden favors established suppliers with clinical evidence, manufacturing quality and post-market systems.

Multiplex donor screening is consolidating test menus

Blood centers increasingly use multiplex NAT to screen several viruses in a single automated workflow. This can reduce hands-on steps, improve throughput and simplify inventory compared with multiple separate molecular assays.

Fourth-generation HIV assays improve early detection

Combined p24 antigen plus HIV-1/2 antibody assays are now well established. FDA's donor-screening list includes Abbott Alinity s HIV Ag/Ab Combo, and newer HIV combo approvals continue to update clinical and donor testing options.

Modern serology platforms are expanding donor-screening menus

FDA licensed Roche Elecsys HBsAg II, Anti-HBc II and Anti-HCV II for donor-related applications in 2024, broadening high-throughput ECLIA options. Competitive value increasingly depends on offering a complete blood-screening menu on one automation platform.

External quality assessment creates an underpenetrated service layer

WHO's 63% global participation figure means many screening laboratories still lack full EQA coverage. Diagnostic suppliers and independent quality organizations can expand controls, proficiency testing, verification materials and training services alongside assay sales.

Emerging-market growth depends on affordable high-sensitivity workflows

Lower-income countries face both higher transfusion-transmissible infection prevalence and weaker laboratory infrastructure. Compact molecular systems, lower-cost immunoassays, dried or stable controls and simplified data management can widen access while preserving sensitivity.

Blood virus testing uses complementary methods rather than one universal technology. Screening algorithms commonly combine serology and, where available or mandated, nucleic-acid testing.

The legacy report scope uses broad laboratory-test categories. Because several of these are not virus-specific by themselves, the analysis focuses on how each category contributes to evaluation of viral infection rather than implying that every test is a direct viral assay.

Hospitals and diagnostic centers are the principal settings for clinical blood-virus testing, while blood-bank screening is a strategically important workflow that cuts across institutional categories.

Commercial demand is best understood by the viral target because screening algorithms, prevalence, treatment pathways and donor-safety requirements differ substantially.

North America

North America has one of the most advanced blood-screening and clinical molecular-testing infrastructures. FDA maintains a broad licensed donor-screening assay list, and U.S. blood centers use high-throughput serology and NAT. The region is a major commercial market for Roche, Abbott, Grifols and other integrated diagnostic platforms, although the exact queued-source regional share is not publicly exposed.

Europe

Europe combines high blood-safety standards with automated immunoassay and molecular platforms. National blood services typically use standardized screening algorithms and external quality systems. EU IVD regulation and centralized procurement create high documentation requirements for suppliers.

Asia-Pacific

The region combines very large population scale with high HBV burden in several countries and expanding laboratory automation. China, Japan, South Korea, India and Southeast Asia vary widely in NAT penetration, creating opportunities across premium automated and lower-cost decentralized systems.

Latin America

Major markets such as Brazil and Mexico operate national or regional blood-safety programs and face ongoing viral-hepatitis and HIV testing needs. Public procurement, reagent cost and local technical support are significant purchasing factors.

Middle East & Africa

Many countries face higher infectious-disease burden but lower EQA participation and laboratory capacity. WHO's blood-safety data highlight persistent screening and quality-system gaps, making affordable assays, training and robust supply chains especially important.

Blood virus testing is governed by both clinical-diagnostic regulation and additional donor-screening requirements. Blood-bank assays face particularly high evidentiary standards because screening results determine whether donated blood is released for transfusion.

Competition is concentrated among multinational diagnostics companies with established analyzer platforms, regulatory dossiers and global service networks. Specialized and rapid-test suppliers remain important in decentralized and lower-resource markets.

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• bioM?rieux SA
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Randox Laboratories Ltd.
• OraSure Technologies, Inc.
• Grifols, S.A.

The public outlook remains structurally positive because blood-donation screening is recurring, viral-hepatitis diagnosis remains underpenetrated globally and high-throughput NAT/serology platforms continue to improve. However, the exact queued publisher extract does not expose the underlying market-size or CAGR values, so this page does not assign a fabricated 2034 revenue figure. The most defensible outlook is therefore qualitative: growth should be strongest in multiplex molecular screening, quality-assured emerging-market testing, broader hepatitis diagnosis and platform consolidation.

The study is structured to support diagnostic-platform strategy, blood-bank procurement, assay portfolio planning, quality-system development and competitive benchmarking across bloodborne viral testing.